Phage Therapy - Part B
- 1st Edition, Volume 201 - September 25, 2023
- Editor: Vijai Singh
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 5 5 6 5 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 5 6 6 - 9
Phage Therapy - Part B, Volume 201 covers bacteriophage and their isolation, screening, synthetic phage, diagnostics, directed evolution, host interaction, and more. The book's ai… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePhage Therapy - Part B, Volume 201 covers bacteriophage and their isolation, screening, synthetic phage, diagnostics, directed evolution, host interaction, and more. The book's aim is to highlight a number of aspects of phage in a way that can help students, researchers, clinicians, entrepreneurs and stakeholders perform research. Sections cover Phages for the treatment of Pseudomonas aeruginosa infection, Phage for the treatment of Vibrio cholerae infection, Phages for the treatment of Mycobacterium species, Phage therapy for gut microbiome, Phages as delivery vehicles, Phage display, Unlocking the potential of Phages: Innovative Approaches to harnessing Bacteriophages as Diagnostic Tools for Human Diseases, and more.
Other sections explore Phage display and human disease detection, Bacteriophage as Cargo and its application in nanomedicine, Phage for drug delivery vehicles, Genome editing for phage design and uses for therapeutic applications, Phage for cancer therapy, and Phage for regenerative medicine and cosmetics.
- Includes sections on phage isolation, screening and characterization
- Covers synthetic phage, phage for diagnostic, directed evolution, and host interaction
- Explores Phage for the treatment of bacterial infections
Basic researchers, Clinicians, Pharmacologists, students
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Phages for treatment Pseudomonas aeruginosa infection
- Abstract
- Abbreviations
- 1 Introduction
- 2 P. aeruginosa
- 3 Phage therapy against P. aeruginosa
- 4 Current regulations and safety guidelines for phage therapy
- 5 Conclusion
- References
- Chapter Two: Phage for treatment of Vibrio cholerae infection
- Abstract
- 1 Introduction
- 2 Virulence factor and pathogenicity
- 3 Clinical indications
- 4 Cholera therapy strategies
- 5 Conclusion and future perspectives
- References
- Chapter Three: Phages for the treatment of Mycobacterium species
- Abstract
- 1 Introduction
- 2 Advantages of using mycobacteriophage therapy as an alternative to anti-tuberculosis drug regimens to treat mycobacterial species
- 3 Mycobacteriophage and TB drugs combination therapy
- 4 Antimicrobial activity of mycobacteriophage endolysins against mycobacteria
- 5 Phage candidates to treat Mycobacterium species
- 6 Mycobacteriophages in animal and human investigations
- 7 Hurdles to overcome
- 8 Conclusion and future perspective
- References
- Chapter Four: Phage therapy in gut microbiome
- Abstract
- Abbreviation
- 1 Introduction
- 2 Microbiota and human health
- 3 Phage and human health
- 4 Phage therapy to gastrointestinal diseases
- 5 Challenges and future directions
- 6 Conclusions
- References
- Chapter Five: Phages as delivery vehicles and phage display
- Abstract
- Abbreviations
- 1 Introduction
- 2 Phage display systems
- 3 Applications of phage display systems
- 4 The potentials and limitations of phage-mediated delivery and phage display
- 5 Conclusion and remarks
- Acknowledgment
- References
- Chapter Six: Unlocking the potential of phages: Innovative approaches to harnessing bacteriophages as diagnostic tools for human diseases
- Abstract
- 1 Introduction
- 2 Types of phages and the mechanisms of action
- 3 Conclusion and future prospectives
- References
- Chapter Seven: Phage display and human disease detection
- Abstract
- 1 Introduction
- 2 Phage display systems
- 3 Display on filamentous phage
- 4 Threadlike phage versus different systems for phage demonstration
- 5 Antibody libraries
- 6 Antibody selection by panning
- 7 Approaches of phage demonstration for diagnostics
- References
- Chapter Eight: Bacteriophage as cargo and its application in nanomedicine
- Abstract
- 1 Introduction
- 2 Bacteriophage as cargo for delivery of biomolecules
- 3 Application of CRISPR against bacterial infections
- 4 Application in cancer treatment
- 5 Application of bacteriophage on vaccination
- 6 Conclusion
- References
- Chapter Nine: Phage for drug delivery vehicles
- Abstract
- 1 Introduction
- 2 Role of bacteriophages as nanocarriers
- 3 Bacteriophages as gene delivery system
- 4 Advantages of filamentous phages as nanocarrier
- 5 Bacteriophages and phage-inspired carriers for targeted delivery of therapeutic drugs
- 6 Conclusion and future outlook
- References
- Chapter Ten: Genome editing for phage design and uses for therapeutic applications
- Abstract
- 1 Introduction
- 2 Why phages for Genome Editing
- 3 Phage Genome Mining and Engineering
- 4 Phage Enzymes
- 5 Treating Infectious Diseases-Phage Therapy
- 6 Phage Treatment for Localized Infection
- 7 Conclusions and Future Perspectives
- References
- Chapter Eleven: Phage for cancer therapy
- Abstract
- 1 Introduction
- 2 The research on the phage for cancer
- 3 Phage for cancer therapy
- 4 Mechanism of phage for cancer therapy
- 5 Conclusion, limitations and future directions
- Acknowledgments
- References
- Chapter Twelve: Phage for regenerative medicine and cosmetics
- Abstract
- Abbreviations
- 1 Introduction
- 2 The research on bacteriophage for regenerative medicine and cosmetics
- 3 Potential of bacteriophage for regenerative medicine
- 4 Potentials of bacteriophage for cosmetics
- 5 Conclusion, limitations, and future directions
- Acknowlegement
- References
- Index
- No. of pages: 300
- Language: English
- Edition: 1
- Volume: 201
- Published: September 25, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780323955652
- eBook ISBN: 9780323955669
VS
Vijai Singh
Dr Vijai Singh is a Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Associate Professor in the Department of Biosciences, School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. Prior this this, he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 100 articles, 70 chapters, 15 books and 3 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.